Compare Mercadolibre Inc (MELI) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

Mercadolibre IncTrade

Regeneron Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

Mercadolibre Inc vs Regeneron Pharmaceuticals Inc — how do they compare? Mercadolibre Inc trades at $1,814 (market cap $92.90B), while Regeneron Pharmaceuticals Inc trades at $670 (market cap $70.47B). The key difference: Mercadolibre Inc is the larger of the two by market cap, and Regeneron Pharmaceuticals Inc pays a 0.56% dividend while Mercadolibre Inc pays none. Which is the better fit depends on your goals.

	MELI	REGN
Market Cap	$92.90B	$70.47B
Sector	Consumer Cyclical	Health
52-Week High	$2.51K	$812.27
52-Week Low	$1.55K	$545.46
Enterprise Value	$99.79B	$64.42B
Dividend Yield	—	0.56%

View details →View details →

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

MELI

View details →

REGN

Telix reports Q2 revenue of $247M, strong growth, and advances in cancer therapy trials.GlobeNewsWire · 1 day agoBullish Lawsuit alleges Regeneron misled investors on drug trial results, causing stock to drop sharply.GlobeNewsWire · 4 days agoBearish Class action lawsuit filed against Regeneron over misleading trial results and stock price drop.GlobeNewsWire · 4 days agoBearish View details →

About Mercadolibre Inc

MercadoLibre runs the largest e-commerce marketplace in Latin America, connecting a network of more than 140 million active users and 1 million active sellers as of the end of 2021 across an 18-country footprint. The company also operates a host of complementary businesses, with shipping solutions (Mercado Envios), a payment and financing operation (Mercado Pago), advertisements (Mercado Clics), classifieds, and a turnkey e-commerce solution (Mercado Shops) rounding out its arsenal. MercadoLibre generates revenue from final value fees, advertising royalties, payment processing, insertion fees, subscription fees, and interest income from consumer and small-business lending.

About Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases